Glioblastoma (GBM) is the most aggressive
brain tumor with poor prognosis and frequent recurrence. The blood-brain barrier (BBB), blood-
brain tumor barrier (BBTB) hinder the entry of
therapeutics into the
glioma region. Vasculogenic mimicry (VM) formed by invasive
glioma cells is also related to recurrence of GBM. VAP is a D-
peptide ligand of
GRP78 protein overexpressed on BBTB, VM, and
glioma cells but not on normal tissues. Besides, p-
hydroxybenzoic acid (pHA) can effectively traverse the BBB. Herein we developed an all-stage
glioma-targeted
cabazitaxel (CBZ) nanocrystal loaded
liposome modified with a "Y" shaped targeting
ligand composed of pHA and VAP (pV-Lip/cNC). The pure drug nanocrystal core provided high drug loading, while
lipid membrane promoted the stability and circulation time. pV-Lip/cNC exhibited excellent
glioma homing, barriers crossing, and
tumor spheroid penetrating capability in vitro. Treatment of pV-Lip/cNC displayed enhanced CBZ accumulation in
glioma and anti-
glioma effect with a median survival time (53 days) significantly longer than that of cNC loaded
liposomes modified with either single
ligand (42 days for VAP and 45 days for pHA) in the murine orthotopic GBM model. These results indicated pV-Lip/cNC could traverse the BBB and BBTB, destruct VM, and finally kill
glioma cells to realize all-stage
glioma therapy.